September 22, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549-3720
| Attention: | Ameen Hamady | |
| Kevin Kuhar | ||
| Deanna Virginio | ||
| Dorrie Yale |
| Re: | PMV Pharmaceuticals, Inc. | ||
Registration Statement on Form S-1 | ||||
File No. 333-248627 |
| Acceleration Request | ||||||
| Requested Date: | September 24, 2020 | |||||
| Requested Time: | 4:00 P.M. Eastern Time | |||||
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, PMV Pharmaceuticals, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-248627) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Megan J. Baier at (212) 497-7736.
[Signature page follows]
Securities and Exchange Commission
September 22, 2020
Page 2
| Sincerely, |
| PMV PHARMACEUTICALS, INC. |
| /s/ David H. Mack |
| David H. Mack, Ph.D. |
| cc: | Winston Kung, PMV Pharmaceuticals, Inc. |
Tony Jeffries, Wilson Sonsini Goodrich & Rosati, P.C.
Megan J. Baier, Wilson Sonsini Goodrich & Rosati, P.C.
Brian J. Cuneo, Latham & Watkins LLP
Richard Kim, Latham & Watkins LLP
